These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9143860)

  • 1. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart.
    Rosenquist M; Brembilla-Perrot B; Meinertz T; Neugebauer A; Crijns HJ; Smeets JL; van der Vring JA; Fromer M; Kobrin I
    Eur J Clin Pharmacol; 1997; 52(1):7-12. PubMed ID: 9143860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S; van der Wall EE; Emanuelsson H; Kobrin I
    J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
    Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the T-type calcium channel blockade with oral mibefradil on the electrophysiologic properties of the human heart.
    Mádle A; Linhartová K; Koza J
    Med Sci Monit; 2001; 7(1):74-7. PubMed ID: 11208497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
    Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
    Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
    Sandmann S; Spitznagel H; Chung O; Xia QG; Illner S; Jänichen G; Rossius B; Daemen MJ; Unger T
    Cardiovasc Res; 1998 Aug; 39(2):339-50. PubMed ID: 9798519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
    Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
    Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemolysis on intravenous administration of a new calcium antagonist.
    Kleinbloesem CH; Siepmann M; Kirch W
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):855-8. PubMed ID: 7564328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
    Heitmann J; Grote L; Knaack L; Köhler U; Hinder M; Peter JH
    Eur J Clin Pharmacol; 1998; 54(9-10):691-6. PubMed ID: 9923569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
    Bernink PJ; Prager G; Schelling A; Kobrin I
    Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
    Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
    J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.